Cargando…

Methyl 1-[(6-meth­oxy-5-methyl­pyrimidin-4-yl)meth­yl]-1H-benzo[d]imidazole-7-carboxyl­ate: a combined X-ray and DFT study

The title compound, C(16)H(16)N(4)O(3), was obtained as a side product during the synthesis of the previously reported anti­tubercular agent N-(2-fluoro­eth­yl)-1-[(6-meth­oxy-5-methyl­pyrimidin-4-yl)meth­yl]-1H-benzo[d]imidazole-4-carboxamide and structurally characterized by X-ray crystallography...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Adrian, Goddard, Richard, Schönefeld, Roy, Imming, Peter, Seidel, Rüdiger W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union of Crystallography 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912325/
https://www.ncbi.nlm.nih.gov/pubmed/36794056
http://dx.doi.org/10.1107/S2414314623000251
Descripción
Sumario:The title compound, C(16)H(16)N(4)O(3), was obtained as a side product during the synthesis of the previously reported anti­tubercular agent N-(2-fluoro­eth­yl)-1-[(6-meth­oxy-5-methyl­pyrimidin-4-yl)meth­yl]-1H-benzo[d]imidazole-4-carboxamide and structurally characterized by X-ray crystallography and computational methods. In the crystal (space group P2(1)/n, Z = 4), the title compound adopts a twisted conformation with a dihedral angle between the benzimidazole and pyrimidine mean planes of 84.11 (3)°. The carboxyl­ate group and the 5-methyl group on the pyrimidine ring exhibit partial disorder. The DFT-optimized mol­ecular structure resembles the structure of the minor component in the crystal. [Image: see text]